
Search
Selected Filter
Filter Results
Displaying 161–170 of 504 news results
-
Jan 7, 2022
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
Jan 5, 2022
Series B new investors included Fidelity Management & Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., D1 Capital Partners, SymBiosis, the Cystic Fibrosis Foundation, and the RD Fund (the venture arm of Foundation Fighting Blindness).
-
Jan 5, 2022
Dr. Thomas Chalberg has been recognized by the Foundation Fighting Blindness for his pioneering contributions to research and development.
-
Dec 22, 2021
Organizations collaborate on inherited macular dystrophy program
The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon Visions Foundation Inherited Macular Dystrophy Program, according to a news release from the organizations.
-
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Dec 15, 2021
Program to have special translational research emphasis on inherited macular dystrophy.
-
Dec 14, 2021
Eyes On Eyecare Raises $1,500 for Foundation Fighting Blindness
Over 1,400 people participated in charitable giving initiative.
-
Dec 13, 2021
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Dec 10, 2021
This December 16th exclusive in-person performance and conversation with the Blind Boys of Alabama will raise awareness for blinding diseases.